Joseph Kim
Senior Vice President Kanaph Therapeutics
Nahm Ju (Joseph) Kim is currently the Senior Vice President at Kanaph Therapeutics, overseeing antibody engineering, ADC process development, and CMC development. With over 20 years of experience in the biopharmaceutical industry, he has led successful programs from early discovery to clinical phases. Prior to joining Kanaph Therapeutics, he held key positions at Samsung Bioepis, contributing to the development of various first-wave biosimilars and the implementation of the Quality by Design (QbD) drug development approach. He earned his B.S. and M.S. degrees from Pohang University of Science and Technology (POSTECH).
Seminars
Wednesday 10th June 2026
Reviewing How to Work With CDMOs Within Korea, Asia & the Rest of the World to Ease Manufacturing & Protect Timelines
12:30 pm
- Prioritizing CDMOs with specialized capabilities in handling complex biologics (e.g., bispecifics) and challenging conjugation processes to ensure high yield and purity specifications are met
- Establishing robust method transfer strategies for advanced analytical characterization (e.g., detecting HMW species or conjugation sites) to ensure data consistency between the sponsor and the CDMO
- Identifying critical process parameters (CPPs) early to mitigate risks associated with scaling up and ensuring a seamless transition from pilot to GMP manufacturing
Wednesday 10th June 2026
Panel Discussion: Hearing Korean ADC Developers’ Perspectives on ADC Development to Accelerate Innovation & Establish South Korea as a Hub of ADC Development
9:00 am
- Honing insights from ADC pioneers in South Korea on cutting-edge research and lessons learned that are driving innovations
- Understanding how partnerships with pharma are accelerating ADC development
- Analyzing the future direction of ADC development to strengthen Korea’s global leadership in next-generation ADC therapeutics
